Carboplatin

別名：NSC 241240, JM-8, CBDCA

製品コード：S1215 純度：99.98%

Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.Solutions are unstable and should be fresh-prepared.DMSO is not recommended to dissolve platinum-based drugs, which can easily lead to drug inactivation.

CAS No. 41575-94-4

サイズ	価格(税別)	在庫状況
50mg	JPY 22000	国内在庫あり
200mg	JPY 41500	国内在庫あり
1g	JPY 145500	国内在庫なし(納期7~10日)
10g	JPY 445500	国内在庫なし(納期7~10日)

代表番号: 045-509-1970\|電子メール：[email protected] よく尋ねられる質問

文献中Selleckの製品使用例（117）

製品安全説明書

現在のバッチを見る：純度： 99.98%

99.98

Carboplatin関連製品

関連製品	Doxorubicin (DOX) HCl Paclitaxel Etoposide Puromycin 2HCl Staurosporine (STS) Vincristine sulfate Bleomycin sulfate Mitomycin C Cyclosporin A Oligomycin A Actinomycin D (Dactinomycin) Daunorubicin HCl Tamoxifen Vinblastine sulfate Doxycycline Hyclate Doxycycline Geldanamycin Honokiol Geneticin (G418 Sulfate) Nigericin sodium salt STZ (Streptozotocin) Novobiocin Sodium (NSC 2382) Dacarbazine Cephalomannine Sodium Monensin (NSC 343257) Rifampin (Rifampicin) 10-Deacetylbaccatin-III Tigecycline Mycophenolic acid Pirarubicin Hygromycin B Embelin Rifabutin (LM427) Clotrimazole Metronidazole Thiotepa Roxithromycin Tobramycin Polymyxin B sulphate Netilmicin Sulfate Neomycin sulfate	もっと見る
関連化合物ライブラリー	FDA-approved Drug Library Natural Product Library Apoptosis Compound Library DNA Damage/DNA Repair compound Library Cell Cycle compound library	もっと見る

Antineoplastic and Immunosuppressive Antibiotics阻害剤の選択性比較

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	活性情報	PMID
H460	Growth Inhibition Assay	7.9 μM	24 h	shows a radiosensitizing effect to X-rays	25599995
A549/CDDP	Growth Inhibition Assay	0.2-4000 μM	72 h	IC50=240 ± 45.7 μM	25625243
A549	Growth Inhibition Assay	0.2-4000 μM	72 h	IC50=126 ± 5.0 μM	25625243
A-549	Fuction Assay	0.5 μM	48 h	inhibits of cell migration	25755690
A-549	Fuction Assay	0.5 μM	48 h	shows aberrant microtubule disruption	25755690
A-549	Apoptosis Assay	0.5 μM	48 h	shows early apoptosis features including blebbing and chromatin condensation	25755690
A-549	Growth Inhibition Assay	0.5 μM	24 h	inhibits cell growth significantly	25755690
MCF7	Growth Inhibition Assay	20 μM	72 h	induces cell death of HP1β-depleted MCF7 cells	25769025
T47D	Growth Inhibition Assay	0-220 μg/ml	72 h	IC50 = 48.9 μM	25837691
MDA-MB-231	Growth Inhibition Assay	0-220 μg/ml	72 h	IC50 = 86 μM	25837691
H1975	Growth Inhibition Assay	25 μM	24 h	inhibits cell growth	25917317
A549	Growth Inhibition Assay	25 μM	24 h	inhibits cell growth	25917317
H1975	Fuction Assay	0/25/50 μM	24 h	upregulates miR-218 expression	25917317
A549	Fuction Assay	0/25/50 μM	24 h	upregulates miR-218 expression	25917317
H1975	Fuction Assay	0/25/50 μM	24 h	downregulates miR-205 expression	25917317
A549	Fuction Assay	0/25/50 μM	24 h	downregulates miR-205 expression	25917317
SKOV3	Apoptosis Assay	2 μg/ml	48 h	induces apoptosis	26125273
SKOV3	Growth Inhibition Assay	0-4 μg/ml	24/48/72 h	inhibits cell viability dose and time dependently	26125273
SKOV3	Growth Inhibition Assay	60 mg/ml	1-5 d	inhibits cell viability time dependently	26137043
Tca8113/PYM	Growth Inhibition Assay	2-25 μM	72 h	inhibits cell viability dose dependently	26137105
Tca8113/CBP	Growth Inhibition Assay	2-25 μM	72 h	inhibits cell viability dose dependently	26137105
Tca8113/ut	Growth Inhibition Assay	2-25 μM	72 h	inhibits cell viability dose dependently	26137105
PC9	Apoptosis Assay	100 µM	72 h	induces apoptosis	24618809
A549	Apoptosis Assay	100 µM	72 h	induces apoptosis	24618809
IMR-32	Fuction Assay	10 μM		induces apoptosis significantly combined with GSK2830371	25658463
CHP-134	Fuction Assay	10 μM		induces apoptosis significantly combined with GSK2830371	25658463
IMR-32	Growth Inhibition Assay	1 μM		inhibits significant cell growth combined with GSK2830371	25658463
CHP-134	Growth Inhibition Assay	1 μM		inhibits significant cell growth combined with GSK2830371	25658463
OSA	Clonogenic Assay	2.5/5 μM		results in lower colony formation as compared to either BMI1 siRNA treatment	26110620
HeLa	Growth Inhibition Assay	5-80 μM		inhibits cell growth dose dependently	25109360
MCF-7	Growth Inhibition Assay	5-80 μM		inhibits cell growth dose dependently	25109360
MDA-MB-231	Growth Inhibition Assay	5-80 μM		inhibits cell growth dose dependently	25109360
OVCAR-3	Growth Inhibition Assay		72 h	IC50=32.6 μM	25520132
SW626	Growth Inhibition Assay		72 h	IC50=97.0 μM	25520132
A2780	Growth Inhibition Assay		72 h	IC50=145.7 μM	25520132
3AO	Growth Inhibition Assay		72 h	IC50=63.4 μM	25520132
OVCAR-8	Growth Inhibition Assay		72 h	IC50=96.0 μM	25520132
ES-2	Growth Inhibition Assay		72 h	IC50=14.6 μM	25520132
SK-OV-3	Growth Inhibition Assay		72 h	IC50=104.8 μM	25520132
RGE	Growth Inhibition Assay		72 h	IC80=63 ± 7.4 μM	25565603
NRK-52E	Growth Inhibition Assay		72 h	IC80=179 ± 9.5 μM	25565603
RGE	Growth Inhibition Assay		72 h	IC50=22 ± 7.4 μM	25565603
NRK-52E	Growth Inhibition Assay		72 h	IC50=100 ± 12.9 μM	25565603
H460	Growth Inhibition Assay		24 h	IC50=7.9 μM	25599995
CaOV3	Growth Inhibition Assay		72 h	IC50=86.1 μM	25068849
OVCAR-3	Growth Inhibition Assay		72 h	IC50=179.5 μM	25068849
OVCAR-5	Growth Inhibition Assay		72 h	IC50=75.7 μM	25068849
SKOV-3	Growth Inhibition Assay		72 h	IC50=504 μM	25068849
OVCAR-4	Growth Inhibition Assay		72 h	IC50=290.6 μM	25068849
OVCAR-8	Growth Inhibition Assay		72 h	IC50=690.2 μM	25068849
MA148	Growth Inhibition Assay		24 h	IC50=83.6 ± 1.4 μg/ml	24831091
A549	Growth Inhibition Assay		24 h	IC50=776.0 ± 1.9 μg/ml	24831091
MDA-MB-231	Growth Inhibition Assay		24 h	IC50=748.0 ± 1.1 μg/ml	24831091
NCI-ADR/RES	Growth Inhibition Assay		24 h	IC50=1753.0 ± 4.4 μg/ml	24831091
MA148	Growth Inhibition Assay		48 h	IC50=28.1 ± 1.0 μg/ml	24831091
A549	Growth Inhibition Assay		48 h	IC50=118.0 ± 1.2 μg/ml	24831091
MDA-MB-231	Growth Inhibition Assay		48 h	IC50=183.0 ± 1.2 μg/ml	24831091
NCI-ADR/RES	Growth Inhibition Assay		48 h	IC50=193.0 ± 1.9 μg/ml	24831091
MA148	Growth Inhibition Assay		72 h	IC50=13.7 ± 1.2 μg/ml	24831091
A549	Growth Inhibition Assay		72 h	IC50=64.3 ± 1.1 μg/ml	24831091
MDA-MB-231	Growth Inhibition Assay		72 h	IC50=99.5 ± 1.1 μg/ml	24831091
NCI-ADR/RES	Growth Inhibition Assay		72 h	IC50=37.4 ± 1.7 μg/ml	24831091
A549	Growth Inhibition Assay		72 h	IC50=152.409 μM	24721323
NCI-H157	Growth Inhibition Assay		72 h	IC50=89.977 μM	24721323
PC9	Growth Inhibition Assay		72 h	GC50=71.6±9.5 µM	24618809
A549	Growth Inhibition Assay		72 h	GC50=136±31.6 µM	24618809
A549	Growth Inhibition Assay		24 h	IC10=1.476 nM	24396437
H1299	Growth Inhibition Assay		24 h	IC10=0.443 nM	24396437
HCC15	Growth Inhibition Assay		24 h	IC10=0.346 nM	24396437
H157	Growth Inhibition Assay		24 h	IC10=0.81 nM	24396437
4T1	Growth Inhibition Assay			IC50=84.62 ± 30.05 μM μM	25277461
A549	Growth Inhibition Assay			IC50=151.56 ± 53.06 μM	25277461
FN-RMG-1-hFUT	Growth Inhibition Assay			IC50=118.8 ± 13.8 mg/L	25726913
RMG-1-hFUT	Growth Inhibition Assay			IC50=58.1 ± 2.4 mg/L	25726913
FN-RMG-1	Growth Inhibition Assay			IC50=40.5 ± 4.2 mg/L μM	25726913
RMG-1	Growth Inhibition Assay			IC50=28.8 ± 3.6 mg/L	25726913
MonoTCC	Growth Inhibition Assay			IC50=5.6 µM	25773167
MegTCC	Growth Inhibition Assay			IC50=4.1 µM	25773167
MCTCC	Growth Inhibition Assay			IC50=2.8 µM	25773167
LCTCC	Growth Inhibition Assay			IC50=3.8 µM	25773167
BALB/3T3	Growth Inhibition Assay			IC50=14.30 ± 6.68 μM	25277461
B16	Growth Inhibition Assay			IC50=64.30 ± 6.81 μM	25277461
DU 145	Growth Inhibition Assay			IC50=35.04 ± 17.54 μM	25277461
FaDu	Growth Inhibition Assay			IC50=45.39 ± 11.50 μM	25277461
HCV-29T	Growth Inhibition Assay			IC50=48.57 ± 22.49 μM	25277461
HL-60	Growth Inhibition Assay			IC50=11.10 ± 4.47 μM	25277461
HT-29	Growth Inhibition Assay			IC50=89.16 ± 18.86 μM	25277461
H146	Growth Inhibition Assay			IC50=49.6±13.1 μM	25124282
H187	Growth Inhibition Assay			IC50=12.7±2.7 μM	25124282
H128	Growth Inhibition Assay			IC50=106.4±9.6 μM	25124282
H69	Growth Inhibition Assay			IC50=76.9±27.8 μM	25124282
H209	Growth Inhibition Assay			IC50=258.1±99.8 μM	25124282
DMS153	Growth Inhibition Assay			IC50=57.8±9.2 μM	25124282
H526	Growth Inhibition Assay			IC50=7.2±1.7 μM	25124282
DMS114	Growth Inhibition Assay			IC50=85.8±12.8 μM	25124282
DMS53	Growth Inhibition Assay			IC50=146.2±36.4 μM	25124282
A2780	Growth Inhibition Assay			IC50=14.0 ± 1.4 μM	24209693
A2780cisR	Growth Inhibition Assay			IC50=48.9 ± 3.9 μM	24209693
A2780ZD0473R	Growth Inhibition Assay			IC50=64.6 ± 3.2 μM	24209693
SKOV-3	Growth Inhibition Assay			IC50=43.4 ± 3.9 μM	24209693
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明

特性

This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).^[6]

Targets

DNA synthesis ^[1]
(A2780, SKOV-3, IGROV-1, HX62 cells)

In Vitro
In vitro	Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. ^[1] Carboplatin also show the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. ^[2]
細胞実験	細胞株	A2780, SKOV3, IGROV-1 and HX62
	濃度	0-200 μM
	反応時間	72 hours
	実験の流れ	3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet.
実験結果図	Methods	Biomarkers	結果図	PMID
	Western blot	pChK-2 / Chk-2 p-p53(S15) / p-p53(S46) / p-p53(S392) / p53 p-p38 / p38 / Cleaved PARP / PARP		30049957
	Immunofluorescence	γH2AX		24348048
	Growth inhibition assay	Cell viability		24348048

In Vivo
In Vivo	In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. ^[1] For the VC8 (Brca2-deficient) xenografts, Carboplatin treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. ^[3]
動物実験	動物モデル	The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank.
	投与量	≤60 mg/kg (When Carboplatin is dissolved in sodium chloride solution, it will induce physio-chemical and pharmacokinetic changes.)
	投与経路	Administered via i.p.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試験 (data from https://clinicaltrials.gov, updated on 2024-01-11)
NCT05846789	Recruiting	Metastatic Breast Cancer\|Triple Negative Breast Cancer\|Estrogen-receptor-low Breast Cancer	Kathy Miller\|Genentech Inc.\|Indiana University	January 2024	Phase 2
NCT06086288	Not yet recruiting	Merkel Cell Carcinoma	Fondazione IRCCS Istituto Nazionale dei Tumori Milano	November 2023	Phase 2
NCT05856695	Recruiting	Small Cell Lung Cancer Extensive Stage	Intergroupe Francophone de Cancerologie Thoracique	November 17 2023	Phase 2

参考
[1] Banerji U, et al. Cancer Chemother Pharmacol. 2008, 62(5), 769-778. [2] Fiebiger W, et al. Clin Transl Oncol. 2011, 13(1), 43-49. [3] Clark CC, et al. Mol Cancer Ther, 2012, doi: 10.1158/1535-7163.MCT-11-0597. [4] Wang H, et al. Clin Cancer Res. 2004, 10(5), 1633-1644. [5] Liu H, et al. Anticancer Res. 2011, 31(9), 2713-2722. [6] Matthew D Hall, et al. Cancer Res. 2014 Jul 15;74(14):3913-22. [7] Groen HJ, et al. Br J Cancer. 1995 Dec; 72(6): 1406–1411. + 展開

参考

+ 展開

化学情報

分子量	371.25	化学式	C₆H₁₂N₂O₄Pt
CAS No.	41575-94-4	SDF	Download Carboplatin SDFをダウンロードする
Smiles	C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]
保管	2 years 4°C(in the dark) powder	溶液状態は不安定なので使用直前に調整してください。少量づつ分包して保管し、都度使い切る事が推奨されます。

In vitro
Batch:

Water : 4.5 mg/mL

Ethanol : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

よくある質問（FAQ）

質問1:
Can you advise what solvent to use and the concentration for S1215 for in vitro use?

回答
DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):